Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing
December 13, 2019 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has entered into an...
Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53
December 12, 2019 18:19 ET
|
Sarepta Therapeutics, Inc.
-- VYONDYS 53 is Sarepta’s second RNA exon-skipping treatment for DMD approved in the U.S. -- -- Commercial distribution of VYONDYS 53 in the U.S. will commence immediately -- -- Information for...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2019 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2019,...
Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies
November 14, 2019 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Agreement leverages StrideBio’s novel, industry-leading, structure-driven capsid engineering platform and expands Sarepta’s early stage gene therapy pipeline – -- Sarepta granted an exclusive...
Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments
November 07, 2019 16:05 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the...
Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference
November 05, 2019 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2019 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2019,...
Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019
October 24, 2019 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2019 financial...
Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
October 04, 2019 08:31 ET
|
Sarepta Therapeutics, Inc.
-- Improvements on functional measures seen in all three participants -- -- Significant reduction in creatine kinase maintained over nine months -- -- Results follow positive and robust expression...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2019 18:03 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30,...